Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Medical therapy
The First People's Hospital of Lianyungang
Aortic Valve Disease
1 trial -
Metformin
The First People's Hospital of Lianyungang
Endometrial Cancer
1 trial -
Metformin hydrochloride sustained release tablets
The First People's Hospital of Lianyungang
Osteoarthritis
1 trial -
Methotrexate
The First People's Hospital of Lianyungang
Knee Osteoarthritis
1 trial -
Mindfulness meditation based on brain-computer interface
The First People's Hospital of Lianyungang
Atrial Fibrillation
1 trial -
Minocycline
The First People's Hospital of Lianyungang
Intracerebral Hemorrhage
1 trial -
Mitoxantrone hydrochloride liposome injection
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
1 trial -
Multiple-dose of Ciprofloxacin prophylaxis
The First People's Hospital of Lianyungang
Kidney Stones
1 trial -
NBP Softgel Capsules
The First People's Hospital of Lianyungang
Migraine
1 trial -
Nab-paclitaxel
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Nitroprusside Sodium
The First People's Hospital of Lianyungang
ST Segment Elevation Myocardial Infarction
1 trial -
Normal Saline (Placebo)
The First People's Hospital of Lianyungang
Disease of Respiratory System
1 trial -
Nutrition Intervention
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Obinutuzumab
The First People's Hospital of Lianyungang
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
Oral carbohydrate (Outfast)
The First People's Hospital of Lianyungang
Gastrointestinal Surgery
1 trial -
PCSK9 inhibitor
The First People's Hospital of Lianyungang
Intracranial Artery Stenosis
1 trial -
PD1-BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
PEG-rhG-CSF
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
PIMS screening
The First People's Hospital of Lianyungang
PGT-A
1 trial -
PSMA PET/CT
The First People's Hospital of Lianyungang
Prostate Adenocarcinoma
1 trial -
PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy
The First People's Hospital of Lianyungang
Prostate Cancer Screening
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
The First People's Hospital of Lianyungang
Breast Cancers
1 trial -
Peak value anti-Xa
The First People's Hospital of Lianyungang
Venous Thromboembolism
1 trial -
Peginterferon Ξ±-2b injection
The First People's Hospital of Lianyungang
Condylomata Acuminata
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources